```html

Malar Rash – Comprehensive Medical Guide

Overview

A malar rash (also called a “butterfly rash”) is a distinct erythematous (red) rash that spreads across the cheeks and bridge of the nose, forming a shape reminiscent of a butterfly’s wings. Although it is most famously associated with systemic lupus erythematosus (SLE), the rash can appear in a variety of other conditions, infections, or as a reaction to medication.

• Who it affects: Primarily young to middle‑aged adults (20‑40 years), with a strong female predominance (≈ 90 % of SLE‑related cases occur in women). However, the rash can occur in children, older adults, and men when caused by other disorders.
• Prevalence: The overall prevalence of SLE in the United States is about 20–150 cases per 100,000 people, and up to 85 % of people with active SLE develop a malar rash at some point during their disease course (Mayo Clinic, 2023).
• Why it matters: Because a malar rash is often an early cutaneous clue to systemic disease, recognizing it promptly can lead to earlier diagnosis and treatment, which improves long‑term outcomes.

Symptoms

The malar rash can vary in appearance, intensity, and accompanying symptoms. Below is a complete symptom list with brief descriptions.

Cutaneous features

• Shape & distribution: Symmetrical, bright red or pink macules that span the cheeks and bridge of the nose, sparing the nasolabial folds.
• Texture: Usually flat (macular) but may become slightly raised (papular) or scaly in chronic cases.
• Photosensitivity: Rash often intensifies after sun exposure; ultraviolet (UV) light can trigger or worsen the eruption.
• Duration: Can appear suddenly and persist for weeks to months; flares may be episodic.
• Color variation: Ranges from pinkish‑white to deep violaceous hue, sometimes with a faint “lacy” border.

Systemic symptoms (when linked to an underlying disease such as SLE)

• Joint pain or swelling (arthralgia/arthritis)
• Fever, fatigue, or malaise
• Oral or nasal ulcers
• Kidney problems (proteinuria, edema)
• Neurologic symptoms (headaches, seizures, cognitive changes)
• Raynaud’s phenomenon (color changes in fingers/toes with cold)

Associated skin findings

• Discoid lesions: Thick, scaly plaques, often on the scalp or ears.
• Subacute cutaneous lupus erythematosus (SCLE): Annular or psoriasiform lesions that may coexist.
• Photosensitivity rash elsewhere: Erythema on chest, arms, or back after sun exposure.

Causes and Risk Factors

A malar rash is a manifestation, not a disease itself. Its underlying causes fall into several categories.

Autoimmune diseases

• Systemic lupus erythematosus (SLE): The most common cause; immune complexes deposit in skin leading to inflammation.
• Dermatomyositis: May present with a heliotrope rash (purple eyelids) and a malar‑like erythema.
• Rheumatoid arthritis (RA) with extra‑articular manifestations.

Infections

• Parvovirus B19: “Fifth disease” in children can cause a facial “slapped cheek” rash mimicking malar distribution.
• Herpes simplex virus (HSV) or varicella‑zoster virus (VZV): May produce vesicular lesions that evolve into erythema.
• Syphilis (secondary stage): Can include a non‑pruritic facial rash.

Drug reactions

• Hydralazine, procainamide, or certain antiepileptics (e.g., carbamazepine) can trigger lupus‑like syndromes with a malar rash.
• Antibiotics (e.g., minocycline) and NSAIDs are occasional culprits.

Other triggers

• Sunlight/UV exposure: UV‑A and UV‑B wavelengths stimulate keratinocyte apoptosis, releasing nuclear antigens that provoke autoimmunity.
• Genetic predisposition: HLA‑DR2, HLA‑DR3 and complement component deficiencies increase susceptibility.
• Hormonal factors: Estrogen may amplify immune responses, partly explaining the female predominance.

Diagnosis

Diagnosing a malar rash involves confirming the cutaneous pattern and identifying the underlying cause.

Clinical evaluation

• History: Onset, triggers (sun, medications), associated systemic symptoms, family history of autoimmune disease.
• Physical exam: Careful inspection of the rash, checking for sparing of the nasolabial folds—a hallmark of lupus‑related rash.

Laboratory tests

• Antinuclear antibody (ANA): Positive in > 95 % of SLE patients (American College of Rheumatology, 2022).
• Anti‑dsDNA and anti‑Smith (Sm) antibodies: More specific for SLE.
• Complement levels (C3, C4): Often low during active disease.
• Complete blood count (CBC) and renal panel: Detect anemia, leukopenia, or kidney involvement.
• Specific infection serologies: Parvovirus B19 IgM, syphilis RPR, HSV PCR if infection suspected.

Skin biopsy

When the diagnosis is uncertain, a 4‑mm punch biopsy examined with routine hematoxylin‑eosin staining and direct immunofluorescence can differentiate lupus erythematosus (showing “interface dermatitis” and deposition of IgG, IgM, C3 at the dermal‑epidermal junction) from other dermatoses.

Imaging (if systemic disease is suspected)

• Renal ultrasound or urinalysis for lupus nephritis.
• Chest X‑ray or CT if pulmonary involvement is a concern.

Treatment Options

Therapy is two‑fold: managing the rash itself and treating the underlying condition.

Topical therapies (first‑line for isolated rash)

• Low‑ to medium‑potency corticosteroids: Hydrocortisone 1 %–2.5 % cream applied twice daily for 1–2 weeks, then tapered.
• Calcineurin inhibitors: Tacrolimus 0.03 % ointment or pimecrolimus 1 % cream can be used for steroid‑sparing, especially on thin facial skin.
• Antimalarial agents (topical): Not standard, but chloroquine gel has shown benefit in small studies.

Systemic medications (when rash reflects systemic disease)

• Hydroxychloroquine (HCQ): 200–400 mg daily is the cornerstone for cutaneous lupus; improves rash in up to 80 % of patients (Cleveland Clinic, 2023).
• Systemic corticosteroids: Prednisone 10–20 mg daily for acute flares; rapid taper to avoid long‑term side effects.
• Immunosuppressants: Azathioprine, methotrexate, or mycophenolate mofetil for steroid‑sparing or refractory disease.
• Biologic agents: Belimumab (anti‑BLyS) approved for SLE; rituximab in severe, refractory cases.
• Antibiotics/antivirals: If an infectious etiology is identified (e.g., doxycycline for secondary syphilis).

Lifestyle and adjunctive measures

• Sun protection: Broad‑spectrum sunscreen SPF ≥ 50, re‑applied every 2 h, and protective clothing.
• Smoking cessation: Smoking impairs HCQ efficacy and worsens rash.
• Stress management: Stress can trigger flares; mindfulness, yoga, or counseling are helpful.

Living with Malar Rash

Daily management focuses on minimizing flare triggers, protecting skin, and adhering to therapy.

• Sun‑smart routine: Wear wide‑brim hats, UV‑blocking sunglasses, and UPF clothing even on cloudy days.
• Gentle skin care: Use fragrance‑free moisturizers, avoid harsh scrubs or alcohol‑based toners.
• Medication adherence: Set daily reminders for HCQ; routine ophthalmology exams every 6–12 months because of rare retinal toxicity.
• Regular follow‑up: Quarterly rheumatology or dermatology visits to monitor disease activity and adjust therapy.
• Psychosocial support: Connect with patient‑support groups (e.g., Lupus Foundation of America) to share experiences and coping strategies.

Prevention

While you cannot completely prevent a malar rash if you have an underlying autoimmune condition, you can reduce the frequency and severity of flares.

• Minimize UV exposure: Daily sunscreen, avoiding peak sun hours (10 am–4 pm), and using window films.
• Control medications: Review drugs with your physician; discontinue known photosensitizing agents when possible.
• Maintain a healthy lifestyle: Balanced diet rich in antioxidants, regular exercise, adequate sleep.
• Vaccinations: Stay up‑to‑date (influenza, pneumococcal, COVID‑19) to lower infection‑related triggers.

Complications

If the malar rash is a sign of uncontrolled systemic disease, several serious complications can arise.

• Lupus nephritis: Leading cause of morbidity; may progress to end‑stage renal disease.
• Cardiovascular disease: Chronic inflammation accelerates atherosclerosis, increasing heart attack and stroke risk.
• Neuropsychiatric lupus: Cognitive impairment, seizures, or mood disorders.
• Skin scarring or pigmentary changes: Chronic rashes may leave post‑inflammatory hyperpigmentation.
• Drug toxicity: Long‑term corticosteroids cause osteoporosis, diabetes, and hypertension; hydroxychloroquine rarely causes retinal toxicity.

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Malar rash.” 2023. mayoclinic.org
• American College of Rheumatology. “2022 Revised Classification Criteria for Systemic Lupus Erythematosus.” Arthritis Care Res (Hoboken). 2022.
• Cleveland Clinic. “Hydroxychloroquine for Lupus Skin Manifestations.” 2023. clevelandclinic.org
• NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Lupus.” 2024. niams.nih.gov
• World Health Organization. “Guidelines for the Management of Systemic Lupus Erythematosus.” 2023.

```